Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

VCEL

Vericel Corp

Dec 12 • 04:00PM ET

57.01

Dollar change -0.91
Percentage change -1.57	%

Healthcare • Biotechnology • USA • NASD

Peers: MDXG ATRC OFIX PODD RVNC ICUI HAE APYX CUTR ENZ

| Held by: IJR IWM VTI VXF XBI IJT SPSM IWO IBB SLYG

Scroll to Statements

Index	RUT	P/E	912.16	EPS (ttm)	0.06	Insider Own	0.91%	Shs Outstand	49.27M	Perf Week	0.87%
Market Cap	2.81B	Forward P/E	122.38	EPS next Y	0.47	Insider Trans	-41.05%	Shs Float	48.91M	Perf Month	2.00%
Income	3.55M	PEG	-	EPS next Q	0.31	Inst Own	103.44%	Short Float	8.21%	Perf Quarter	24.29%
Sales	226.84M	P/S	12.40	EPS this Y	275.98%	Inst Trans	-0.58%	Short Ratio	10.19	Perf Half Y	31.51%
Book/sh	5.23	P/B	10.91	EPS next Y	278.16%	ROA	1.00%	Short Interest	4.02M	Perf Year	66.89%
Cash/sh	2.40	P/C	23.77	EPS next 5Y	-	ROE	1.54%	52W Range	32.31 - 61.49	Perf YTD	60.10%
Dividend Est.	-	P/FCF	-	EPS past 5Y	19.85%	ROI	1.02%	52W High	-7.29%	Beta	1.73
Dividend TTM	-	Quick Ratio	4.23	Sales past 5Y	17.25%	Gross Margin	71.47%	52W Low	76.45%	ATR (14)	2.33
Dividend Ex-Date	-	Current Ratio	4.61	EPS Y/Y TTM	135.98%	Oper. Margin	-0.54%	RSI (14)	59.09	Volatility	3.79% 4.32%
Employees	314	Debt/Eq	0.38	Sales Y/Y TTM	22.48%	Profit Margin	1.56%	Recom	1.00	Target Price	62.00
Option/Short	Yes / Yes	LT Debt/Eq	0.36	EPS Q/Q	76.04%	Payout	-	Rel Volume	0.71	Prev Close	57.92
Sales Surprise	4.89%	EPS Surprise	58.51%	Sales Q/Q	27.04%	Earnings	Nov 07 BMO	Avg Volume	394.07K	Price	57.01
SMA20	0.27%	SMA50	14.90%	SMA200	19.44%	Trades		Volume	279,238	Change	-1.57%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-09-24	Initiated	Canaccord Genuity	Buy	$57
Jun-20-24	Initiated	TD Cowen	Buy	$55
Jan-25-24	Upgrade	Truist	Hold → Buy	$39 → $51
Aug-08-23	Upgrade	BTIG Research	Neutral → Buy	$39
Nov-10-22	Downgrade	BTIG Research	Buy → Neutral
Nov-09-22	Downgrade	Truist	Buy → Hold
Oct-14-22	Resumed	Stephens	Overweight	$40
Jan-11-21	Downgrade	Oppenheimer	Outperform → Perform
Dec-18-20	Initiated	Stephens	Overweight	$31
Sep-17-20	Initiated	Truist	Buy	$24
Oct-09-19	Initiated	H.C. Wainwright	Buy	$19
Feb-28-19	Downgrade	Needham	Buy → Hold
Aug-08-18	Reiterated	Needham	Buy	$15 → $14
Jul-16-18	Upgrade	Ladenburg Thalmann	Neutral → Buy
Apr-04-18	Initiated	Leerink Partners	Outperform	$15
Mar-06-18	Reiterated	Needham	Buy	$5 → $15
Mar-06-18	Downgrade	Ladenburg Thalmann	Buy → Neutral
Mar-05-18	Reiterated	BTIG Research	Buy	$8 → $13
Jun-21-17	Initiated	BTIG Research	Buy	$6
Mar-13-17	Reiterated	Needham	Buy	$9 → $6

Show Previous Ratings

Nov-11-24 02:06PM	Vericel Stock Sees RS Rating Shoot Higher (Investor's Business Daily) +5.15%
Nov-08-24 04:03AM	Vericel Corp (VCEL) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic FDA ... (GuruFocus.com) +7.94%
Nov-07-24 09:10AM	Vericel Corporation (VCEL) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:55AM	Vericel Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-06-24 07:15AM	Vericel Corp (VCEL) Q3 2024 Earnings Report Preview: What To Look For (GuruFocus.com) +7.35%
08:30AM	Loading…
Oct-24-24 08:30AM	Vericel to Report Third-Quarter 2024 Financial Results on November 7, 2024 (GlobeNewswire)
Oct-22-24 09:31AM	Vericel Corp. (VCEL) Cooled Down in Q3 After a 20% Rise in the First Half (Insider Monkey)
Oct-18-24 03:04PM	State Street Corp's Strategic Reduction in Vericel Corp Holdings (GuruFocus.com)
Oct-09-24 03:44PM	Vericel Corp (VCEL) Q2 2024 Earnings Call Highlights: Record Revenue and Strategic Growth ... (GuruFocus.com)
Aug-29-24 09:17AM	Vericel to Present at the Morgan Stanley Global Healthcare Conference on Friday, September 6, 2024 (GlobeNewswire)
Aug-26-24 07:45AM	Vericel Announces FDA Approval and Commercial Availability of MACI Arthro (GlobeNewswire)
Aug-16-24 10:33AM	MediWound and Vericel win FDA paediatric label expansion for NexoBrid (Medical Device Network)
Aug-15-24 04:05PM	Vericel Announces FDA Approval of NexoBrid for the Treatment of Pediatric Patients with Severe Thermal Burns (GlobeNewswire)
Aug-07-24 08:30AM	Vericel to Present at the Canaccord Genuity Growth Conference on Wednesday, August 14, 2024 (GlobeNewswire)
Aug-05-24 12:00PM	What Makes Vericel (VCEL) a New Strong Buy Stock (Zacks)
09:05AM	Loading…
Aug-01-24 09:05AM	Vericel Corporation (VCEL) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -5.94%
07:55AM	Vericel Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-29-24 03:45PM	AppFolio, Inc. (APPF): One of Ray Dalio's Top 10 Growth Stock Picks Right Now? (Insider Monkey)
Jul-22-24 08:30AM	Vericel Announces Appointment of Karen Mahoney as Chief Human Resources Officer (GlobeNewswire)
Jul-18-24 08:30AM	Vericel to Report Second-Quarter 2024 Financial Results on August 1, 2024 (GlobeNewswire)
Jul-16-24 07:01PM	Insider Sale: CFO Mara Joseph Anthony Jr Sells 5,000 Shares of Vericel Corp (VCEL) (GuruFocus.com)
Jul-02-24 09:58AM	Should You Consider Adding Vericel Corporation (VCEL) to Your Portfolio? (Insider Monkey)
Jun-27-24 02:03PM	The 3 Highest-Rated Medical Stocks You Can Buy Today (InvestorPlace)
Jun-25-24 07:22AM	Factors Behind Vericel Corporation (VCEL) Stock's Positive Momentum (Insider Monkey)
Jun-20-24 09:54AM	Spirit Aero downgraded, Skyworks upgraded: Wall Street's top analyst calls (The Fly)
Jun-11-24 08:30AM	Vericel to Present at the Truist Securities MedTech Conference on Tuesday, June 18, 2024 (GlobeNewswire)
May-22-24 08:30AM	Vericel to Present at the Leerink Partners Healthcare Crossroads Conference on Wednesday, May 29, 2024 (GlobeNewswire)
May-21-24 06:42AM	Multiple Factors Pushed Vericel Corp. (VCEL) in Q1 (Insider Monkey)
May-09-24 03:28PM	Vericel Corporation (NASDAQ:VCEL) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:08AM	Vericel Corp (VCEL) Q1 2024 Earnings Call Transcript Highlights: Robust Revenue Growth and ... (GuruFocus.com)
11:24PM	Loading…
May-08-24 11:24PM	Q1 2024 Vericel Corp Earnings Call (Thomson Reuters StreetEvents)
09:35AM	Vericel Corp (VCEL) Surpasses Q1 Revenue Forecasts with Strong Growth in Core Markets (GuruFocus.com)
09:10AM	Vericel Q1 Loss Narrows, Revenue Increases; 2024 Outlook Lifted -- Shares Rise Pre-Bell (MT Newswires)
07:55AM	Vericel Reports First Quarter 2024 Financial Results and Raises Full-Year 2024 Financial Guidance (GlobeNewswire)
Apr-24-24 08:30AM	Vericel to Report First-Quarter 2024 Financial Results on May 8, 2024 (GlobeNewswire)
Mar-29-24 07:01PM	Director ZERBE ROBERT L MD Sells Shares of Vericel Corp (VCEL) (GuruFocus.com)
Mar-28-24 01:48PM	Land Developer And A Specialty Medical Stock Burst Into Buy Zones (Investor's Business Daily)
Mar-15-24 07:00PM	Vericel Corp President and CEO Dominick Colangelo Sells 35,000 Shares (GuruFocus.com)
Mar-01-24 09:30AM	Vericel Corporation (NASDAQ:VCEL) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-29-24 11:37PM	Q4 2023 Vericel Corp Earnings Call (Thomson Reuters StreetEvents)
09:05AM	Vericel Corporation (VCEL) Q4 Earnings Beat Estimates (Zacks)
08:32AM	Vericel Corp (VCEL) Reports Robust Revenue and EBITDA Growth in Q4 and Full-Year 2023 (GuruFocus.com)
07:55AM	Vericel Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Full-Year 2024 Financial Guidance (GlobeNewswire)
Feb-27-24 08:30AM	Vericel to Present at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024 (GlobeNewswire)
Feb-22-24 12:00PM	Are You Looking for a Top Momentum Pick? Why Vericel Corporation (VCEL) is a Great Choice (Zacks)
Feb-18-24 03:00AM	Vericel Corp President and CEO Dominick Colangelo Sells 35,000 Shares (GuruFocus.com)
Feb-15-24 10:00AM	Vericel Corporation (VCEL) to Report Q4 Results: Wall Street Expects Earnings Growth (Zacks)
08:50AM	Vericel Corporation (VCEL) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
08:30AM	Vericel to Report Fourth-Quarter and Full-Year 2023 Financial Results on February 29, 2024 (GlobeNewswire)
Feb-05-24 08:30AM	Vericel to Present at the Canaccord Genuity Musculoskeletal Conference on Monday, February 12, 2024 (GlobeNewswire)
Jan-30-24 11:01PM	Director ZERBE ROBERT L MD Sells Shares of Vericel Corp (VCEL) (GuruFocus.com)
08:50AM	Recent Price Trend in Vericel Corporation (VCEL) is Your Friend, Here's Why (Zacks)
Jan-25-24 09:49AM	Tesla, Boeing downgraded: Wall Street's top analyst calls (The Fly)
Jan-24-24 07:01PM	Director ZERBE ROBERT L MD Sells 8,000 Shares of Vericel Corp (VCEL) (GuruFocus.com)
Jan-19-24 08:28PM	Vericel Corp President and CEO Dominick Colangelo Sells 33,452 Shares (GuruFocus.com) +5.95%
Jan-09-24 08:47AM	Vericel Corporation (VCEL) Moves 7.0% Higher: Will This Strength Last? (Zacks) +7.24%
07:55AM	Vericel Announces Preliminary Full-Year and Fourth Quarter 2023 Financial Results (GlobeNewswire)
Jan-03-24 08:30AM	Vericel to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 (GlobeNewswire)
Dec-17-23 03:01AM	Insider Sell: Director Paul Wotton Offloads 5,000 Shares of Vericel Corp (VCEL) (GuruFocus.com)
Dec-09-23 03:05AM	Insider Sell: President and CEO Dominick Colangelo Sells 24,397 Shares of Vericel Corp (VCEL) (GuruFocus.com)
Dec-02-23 05:04AM	Insider Sell: COO Michael Halpin Sells 17,447 Shares of Vericel Corp (VCEL) (GuruFocus.com)
Nov-23-23 07:04AM	Insider Sell: Chief Medical Officer Jonathan Hopper Sells 5,000 Shares of Vericel Corp (VCEL) (GuruFocus.com)
Nov-16-23 05:35PM	3 Biotech Stocks That Could Boom or Bust by 2025 (InvestorPlace)
Nov-10-23 09:52PM	3 Strong Buy Stocks Set to Take Off in the Coming Months (InvestorPlace)
Nov-09-23 03:56PM	Vericel Corporation (NASDAQ:VCEL) Q3 2023 Earnings Call Transcript (Insider Monkey) -8.05%
Nov-08-23 03:30PM	Vericel Corp (VCEL) Reports Strong Q3 2023 Results and Raises Full-Year Guidance (GuruFocus.com)
07:55AM	Vericel Reports Third Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance (GlobeNewswire)
Nov-07-23 08:30AM	Vericel to Present at the Stephens Annual Investment Conference (GlobeNewswire)
Nov-01-23 10:01AM	Vericel Corporation (VCEL) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-25-23 08:30AM	Vericel to Report Third-Quarter 2023 Financial Results on November 8, 2023 (GlobeNewswire)
Oct-24-23 01:22AM	Zacks Investment Ideas feature highlights: Fresenius Medical Care, Vericel and ImmunoGen (Zacks) +5.70%
Oct-23-23 05:59PM	Top Medical Stocks to Buy Amid Recent Market Volatility (Zacks)
Oct-16-23 10:23AM	Wayfair upgraded, JD.com downgraded: Wall Street's top analyst calls (The Fly) +6.34%
Sep-28-23 08:30AM	Vericel Announces Publication of Positive Results from Phase 3 Debride and Protect (DETECT) Study of Thermal Burn Patients Treated with NexoBrid (GlobeNewswire)
Sep-20-23 04:30PM	Vericel Announces U.S. Commercial Availability of NexoBrid® (anacaulase-bcdb) for the Treatment of Severe Thermal Burns in Adults (GlobeNewswire) +5.14%
Sep-06-23 08:30AM	Vericel to Present at the Morgan Stanley Global Healthcare Conference (GlobeNewswire)
Aug-10-23 01:48AM	Vericel Corp. (VCEL) Rose on Positive Trend in the Industry (Insider Monkey)
Aug-02-23 09:05AM	Vericel Corporation (VCEL) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:55AM	Vericel Reports Second Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance (GlobeNewswire)
Jul-23-23 11:44AM	11 Best Healthcare Stocks Under $50 (Insider Monkey)
Jul-20-23 08:30AM	Vericel to Report Second-Quarter 2023 Financial Results on August 2, 2023 (GlobeNewswire)
Jul-10-23 09:30AM	Vericel (NASDAQ:VCEL) shareholders are still up 286% over 5 years despite pulling back 4.5% in the past week (Simply Wall St.)
Jun-21-23 08:00PM	VCEL: What does Argus have to say about VCEL? (Argus Research)
May-10-23 09:05AM	Vericel Corporation (VCEL) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:55AM	Vericel Reports First Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance (GlobeNewswire)
May-02-23 09:00AM	Dimension Inx announces the addition of biotech industry leaders Paul K. Wotton, Ph.D., as Board Director and Chris Ehrlich as Senior Advisor (PR Newswire)
Apr-26-23 08:00PM	VCEL: Lowering target price to $32.00 (Argus Research)
08:30AM	Vericel to Report First-Quarter 2023 Financial Results on May 10, 2023 (GlobeNewswire)
Apr-24-23 02:06AM	Allogene Therapeutics (ALLO) Surges 8.4%: Is This an Indication of Further Gains? (Zacks)
Apr-17-23 03:03PM	Little Excitement Around Vericel Corporation's (NASDAQ:VCEL) Revenues (Simply Wall St.)
Feb-28-23 08:30AM	Vericel to Present at the Canaccord Genuity Musculoskeletal Conference on Tuesday, March 7, 2023 (GlobeNewswire)
Feb-23-23 09:45AM	Vericel Corporation (VCEL) Q4 Earnings Surpass Estimates (Zacks) +7.29%
07:55AM	Vericel Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Full-Year 2023 Financial Guidance (GlobeNewswire)
Feb-09-23 08:00AM	Vericel to Report Fourth-Quarter 2022 Financial Results on February 23, 2023 (GlobeNewswire)
Jan-31-23 07:19AM	Vericel (NASDAQ:VCEL) shareholders are still up 275% over 5 years despite pulling back 5.7% in the past week (Simply Wall St.)
Jan-11-23 10:24PM	Vericel Corporation (VCEL) Surges 16.3%: Is This an Indication of Further Gains? (Zacks) +6.95%
Jan-10-23 07:55AM	Vericel Announces Preliminary Fourth-Quarter and Full-Year 2022 Financial Results and Accelerated Launch Timeline for MACI Arthroscopic Program (GlobeNewswire) +16.27%
Jan-04-23 08:34AM	Vericel to Present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 (GlobeNewswire)
Dec-30-22 01:42PM	Vericel scores FDA approval for $142M burn treatment (American City Business Journals)
05:26AM	FDA Approves MediWound's NexoBrid For Burn Treatment (Benzinga)

Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Wotton Paul K	Director	Dec 04 '24	Sale	58.72	2,600	152,672	27,402	Dec 05 04:05 PM
Wotton Paul K	Director	Dec 04 '24	Proposed Sale	83.76	2,600	217,782		Dec 04 10:37 AM
Hopper Jonathan Mark	Chief Medical Officer	Dec 02 '24	Option Exercise	16.66	10,000	166,600	68,371	Dec 03 04:05 PM
Hopper Jonathan Mark	Chief Medical Officer	Dec 02 '24	Sale	58.72	10,000	587,200	58,371	Dec 03 04:05 PM
Hopper Jonathan Mark	Officer	Dec 02 '24	Proposed Sale	57.95	10,000	579,500		Dec 02 03:14 PM
ZERBE ROBERT L MD	Director	Nov 22 '24	Option Exercise	13.05	2,500	32,625	29,095	Nov 25 04:05 PM
ZERBE ROBERT L MD	Director	Nov 22 '24	Sale	60.00	2,500	150,000	26,595	Nov 25 04:05 PM
ZERBE ROBERT L MD	Director	Nov 22 '24	Proposed Sale	60.00	2,500	150,000		Nov 22 04:26 PM
MCLAUGHLIN KEVIN F	Director	Nov 13 '24	Option Exercise	3.74	7,000	26,180	18,900	Nov 15 04:05 PM
MCLAUGHLIN KEVIN F	Director	Nov 13 '24	Sale	55.54	7,000	388,780	11,900	Nov 15 04:05 PM
Colangelo Dominick	President and CEO	Nov 13 '24	Option Exercise	3.02	17,500	52,850	238,437	Nov 15 04:05 PM
Colangelo Dominick	President and CEO	Nov 14 '24	Option Exercise	3.02	17,500	52,850	238,437	Nov 15 04:05 PM
Colangelo Dominick	President and CEO	Nov 13 '24	Sale	55.57	17,500	972,475	220,937	Nov 15 04:05 PM
Colangelo Dominick	President and CEO	Nov 14 '24	Sale	53.93	17,500	943,775	220,937	Nov 15 04:05 PM
Colangelo Dominick	Officer	Nov 14 '24	Proposed Sale	53.93	17,500	943,758		Nov 14 04:11 PM
Colangelo Dominick	Officer	Nov 13 '24	Proposed Sale	55.57	17,500	972,477		Nov 13 04:29 PM
MCLAUGHLIN KEVIN F	Director	Nov 13 '24	Proposed Sale	55.54	7,000	388,802		Nov 13 04:09 PM
ZERBE ROBERT L MD	Director	Nov 11 '24	Option Exercise	13.05	2,500	32,625	29,095	Nov 13 04:05 PM
ZERBE ROBERT L MD	Director	Nov 12 '24	Option Exercise	13.05	2,500	32,625	29,095	Nov 13 04:05 PM
ZERBE ROBERT L MD	Director	Nov 12 '24	Sale	57.50	2,500	143,750	26,595	Nov 13 04:05 PM
ZERBE ROBERT L MD	Director	Nov 11 '24	Sale	55.00	2,500	137,500	26,595	Nov 13 04:05 PM
ZERBE ROBERT L MD	Director	Nov 12 '24	Proposed Sale	57.50	2,500	143,750		Nov 12 12:42 PM
Hagen Heidi	Director	Oct 17 '24	Option Exercise	3.74	10,000	37,400	28,650	Oct 21 04:05 PM
Colangelo Dominick	President and CEO	Oct 16 '24	Option Exercise	3.02	17,500	52,850	238,437	Oct 18 04:05 PM
Colangelo Dominick	President and CEO	Oct 17 '24	Option Exercise	3.02	17,500	52,850	238,437	Oct 18 04:05 PM
Colangelo Dominick	President and CEO	Oct 16 '24	Sale	41.38	17,500	724,150	220,937	Oct 18 04:05 PM
Colangelo Dominick	President and CEO	Oct 17 '24	Sale	40.34	17,500	705,950	220,937	Oct 18 04:05 PM
GILMAN STEVEN C	Director	Oct 16 '24	Option Exercise	13.05	5,833	76,121	16,833	Oct 18 04:05 PM
GILMAN STEVEN C	Director	Oct 16 '24	Sale	41.36	5,833	241,253	11,000	Oct 18 04:05 PM
Colangelo Dominick	Officer	Oct 17 '24	Proposed Sale	40.34	17,500	705,983		Oct 17 04:27 PM
Colangelo Dominick	Officer	Oct 16 '24	Proposed Sale	41.38	17,500	724,173		Oct 16 04:43 PM
GILMAN STEVEN C	Director	Oct 16 '24	Proposed Sale	41.36	5,833	241,270		Oct 16 04:31 PM
GILMAN STEVEN C	Director	Oct 02 '24	Option Exercise	13.05	5,833	76,121	16,833	Oct 04 04:06 PM
GILMAN STEVEN C	Director	Oct 02 '24	Sale	40.35	5,833	235,362	11,000	Oct 04 04:06 PM
GILMAN STEVEN C	Director	Oct 02 '24	Proposed Sale	40.35	5,833	235,373		Oct 02 04:54 PM
SIEGAL JONATHAN	Principal Accounting Officer	Sep 30 '24	Option Exercise	0.00	937	0	2,061	Oct 02 04:06 PM
SIEGAL JONATHAN	Principal Accounting Officer	Oct 01 '24	Sale	41.90	568	23,799	1,124	Oct 02 04:06 PM
SIEGAL JONATHAN	Officer	Oct 01 '24	Proposed Sale	41.90	568	23,799		Oct 01 01:16 PM
GILMAN STEVEN C	Director	Sep 18 '24	Option Exercise	13.05	5,834	76,134	16,834	Sep 20 04:05 PM
GILMAN STEVEN C	Director	Sep 18 '24	Sale	45.54	5,834	265,680	11,000	Sep 20 04:05 PM
GILMAN STEVEN C	Director	Sep 18 '24	Proposed Sale	45.54	5,834	265,674		Sep 18 04:10 PM
Colangelo Dominick	President and CEO	Sep 11 '24	Option Exercise	3.02	17,500	52,850	238,437	Sep 13 04:05 PM
Colangelo Dominick	President and CEO	Sep 12 '24	Option Exercise	3.02	17,500	52,850	238,437	Sep 13 04:05 PM
Colangelo Dominick	President and CEO	Sep 12 '24	Sale	43.90	17,500	768,250	220,937	Sep 13 04:05 PM
Colangelo Dominick	President and CEO	Sep 11 '24	Sale	43.37	17,500	758,975	220,937	Sep 13 04:05 PM
Colangelo Dominick	Officer	Sep 12 '24	Proposed Sale	43.90	17,500	768,329		Sep 12 04:16 PM
Colangelo Dominick	Officer	Sep 11 '24	Proposed Sale	43.37	17,500	758,911		Sep 11 04:55 PM
GILMAN STEVEN C	Director	Sep 04 '24	Option Exercise	3.74	5,000	18,700	16,000	Sep 05 04:06 PM
GILMAN STEVEN C	Director	Sep 04 '24	Sale	48.58	5,000	242,900	11,000	Sep 05 04:06 PM
Hopper Jonathan Mark	Chief Medical Officer	Sep 03 '24	Option Exercise	10.95	10,000	109,500	68,229	Sep 05 04:05 PM
Hopper Jonathan Mark	Chief Medical Officer	Sep 03 '24	Sale	49.83	10,000	498,300	58,229	Sep 05 04:05 PM
GILMAN STEVEN C	Director	Sep 04 '24	Proposed Sale	48.99	5,000	244,950		Sep 04 10:25 AM
Hopper Jonathan Mark	Officer	Sep 03 '24	Proposed Sale	51.22	10,000	512,200		Sep 03 01:27 PM
Colangelo Dominick	President and CEO	Aug 15 '24	Option Exercise	3.02	17,500	52,850	238,437	Aug 16 04:05 PM
Colangelo Dominick	President and CEO	Aug 14 '24	Option Exercise	3.02	17,500	52,850	238,437	Aug 16 04:05 PM
Colangelo Dominick	President and CEO	Aug 15 '24	Sale	46.24	17,500	809,200	220,937	Aug 16 04:05 PM
Colangelo Dominick	President and CEO	Aug 14 '24	Sale	45.17	17,500	790,475	220,937	Aug 16 04:05 PM
Colangelo Dominick	Officer	Aug 15 '24	Proposed Sale	46.24	17,500	809,196		Aug 15 05:03 PM
Colangelo Dominick	Officer	Aug 14 '24	Proposed Sale	45.17	17,500	790,400		Aug 14 04:17 PM
MCLAUGHLIN KEVIN F	Director	Aug 07 '24	Option Exercise	3.74	7,000	26,180	16,900	Aug 09 04:05 PM
MCLAUGHLIN KEVIN F	Director	Aug 07 '24	Sale	45.94	7,000	321,580	11,900	Aug 09 04:05 PM
MCLAUGHLIN KEVIN F	Director	Aug 07 '24	Proposed Sale	45.94	7,000	321,596		Aug 07 04:11 PM
Colangelo Dominick	President and CEO	Jul 17 '24	Option Exercise	3.02	17,500	52,850	238,437	Jul 19 04:05 PM
Colangelo Dominick	President and CEO	Jul 18 '24	Option Exercise	3.02	17,500	52,850	238,437	Jul 19 04:05 PM
Colangelo Dominick	President and CEO	Jul 17 '24	Sale	51.55	17,500	902,125	220,937	Jul 19 04:05 PM
Colangelo Dominick	President and CEO	Jul 18 '24	Sale	51.40	17,500	899,500	220,937	Jul 19 04:05 PM
Flynn Sean C.	Chief Legal Officer	Jul 16 '24	Option Exercise	16.25	15,000	243,750	15,707	Jul 18 04:05 PM
Flynn Sean C.	Chief Legal Officer	Jul 16 '24	Sale	52.18	15,000	782,700	707	Jul 18 04:05 PM
Mara Joseph Anthony Jr	Chief Financial Officer	Jul 12 '24	Sale	50.00	5,000	250,000	14,436	Jul 16 04:05 PM
SIEGAL JONATHAN	Principal Accounting Officer	Jul 05 '24	Sale	45.00	545	24,525	1,033	Jul 09 04:05 PM
Flynn Sean C.	Chief Legal Officer	Jun 21 '24	Option Exercise	16.25	6,772	110,045	7,259	Jun 24 06:21 PM
Flynn Sean C.	Chief Legal Officer	Jun 20 '24	Option Exercise	16.25	6,754	109,752	7,241	Jun 24 06:21 PM
Flynn Sean C.	Chief Legal Officer	Jun 24 '24	Option Exercise	16.25	1,474	23,952	1,961	Jun 24 06:21 PM
Flynn Sean C.	Chief Legal Officer	Jun 21 '24	Sale	45.02	6,772	304,875	487	Jun 24 06:21 PM
Flynn Sean C.	Chief Legal Officer	Jun 20 '24	Sale	45.04	6,754	304,200	487	Jun 24 06:21 PM
Flynn Sean C.	Chief Legal Officer	Jun 24 '24	Sale	45.84	1,474	67,568	487	Jun 24 06:21 PM
Colangelo Dominick	President and CEO	Jun 12 '24	Option Exercise	3.02	17,500	52,850	238,252	Jun 14 04:05 PM
Colangelo Dominick	President and CEO	Jun 13 '24	Option Exercise	3.02	17,500	52,850	238,252	Jun 14 04:05 PM
Colangelo Dominick	President and CEO	Jun 12 '24	Sale	44.12	17,500	772,100	220,752	Jun 14 04:05 PM
Colangelo Dominick	President and CEO	Jun 13 '24	Sale	43.10	17,500	754,250	220,752	Jun 14 04:05 PM
Hopper Jonathan Mark	Chief Medical Officer	May 20 '24	Option Exercise	10.95	10,000	109,500	68,116	May 21 04:07 PM
Hopper Jonathan Mark	Chief Medical Officer	May 20 '24	Sale	49.99	10,000	499,900	58,116	May 21 04:07 PM
Halpin Michael	Chief Operating Officer	May 17 '24	Option Exercise	5.39	5,195	28,017	6,284	May 21 04:05 PM
Colangelo Dominick	President and CEO	May 15 '24	Option Exercise	3.02	17,500	52,850	238,252	May 17 04:05 PM
Colangelo Dominick	President and CEO	May 16 '24	Option Exercise	3.02	17,500	52,850	238,252	May 17 04:05 PM
Colangelo Dominick	President and CEO	May 15 '24	Sale	49.67	17,500	869,225	220,752	May 17 04:05 PM
Colangelo Dominick	President and CEO	May 16 '24	Sale	47.85	17,500	837,375	220,752	May 17 04:05 PM
Colangelo Dominick	President and CEO	Apr 30 '24	Option Exercise	11.79	25,445	299,977	220,752	May 01 04:05 PM
Colangelo Dominick	President and CEO	Apr 17 '24	Option Exercise	3.02	17,500	52,850	212,807	Apr 19 04:05 PM
Colangelo Dominick	President and CEO	Apr 18 '24	Option Exercise	3.02	17,500	52,850	212,807	Apr 19 04:05 PM
Colangelo Dominick	President and CEO	Apr 17 '24	Sale	46.47	17,500	813,225	195,307	Apr 19 04:05 PM
Colangelo Dominick	President and CEO	Apr 18 '24	Sale	44.59	17,500	780,325	195,307	Apr 19 04:05 PM
Rubino Alan L	Director	Apr 09 '24	Option Exercise	4.12	3,000	12,360	20,594	Apr 11 04:05 PM
ZERBE ROBERT L MD	Director	Mar 27 '24	Option Exercise	3.74	3,278	12,260	26,673	Mar 29 04:05 PM
ZERBE ROBERT L MD	Director	Mar 27 '24	Sale	51.57	3,278	169,046	23,395	Mar 29 04:05 PM
Colangelo Dominick	President and CEO	Mar 13 '24	Option Exercise	3.02	17,500	52,850	212,370	Mar 15 04:07 PM
Colangelo Dominick	President and CEO	Mar 14 '24	Option Exercise	3.02	17,500	52,850	212,370	Mar 15 04:07 PM
Colangelo Dominick	President and CEO	Mar 13 '24	Sale	44.67	17,500	781,725	194,870	Mar 15 04:07 PM
Colangelo Dominick	President and CEO	Mar 14 '24	Sale	44.02	17,500	770,350	194,870	Mar 15 04:07 PM
Halpin Michael	Chief Operating Officer	Mar 11 '24	Sale	44.71	7,874	352,047	949	Mar 13 04:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VCEL

Vericel Corp

Upgrade your FINVIZ experience